ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25883-25896

  Chen, Qiongrong ^a,b   Song, Shumei ^a   Wei, Shaozhong ^b   Liu, Bin ^a   Honjo, Soichiro ^a   Scott, Ailing ^a   Jin, Jiankang ^a   Ma, Lang ^a   Zhu, Haitao ^a   Skinner, Heath D ^a   Johnson, Randy L ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

5 fluorouracil; ABT 263; Cancer stem cells; Esophageal cancer; Stemness pathways

Indexed keywords

BETA CATENIN; FLUOROURACIL; NAVITOCLAX; REGULATOR PROTEIN; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; WNT PROTEIN; YES ASSOCIATED PROTEIN; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SOX9 PROTEIN, HUMAN; SULFONAMIDE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ESOPHAGUS CANCER; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOPLASTIC STEM CELLS; PHOSPHOPROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; SULFONAMIDES; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944474787     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4540     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
2. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. The New England journal of medicine. 2012; 366:2074-2084.
3. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, et al. Esophageal and esophagogastric junction cancers. Journal of the National Comprehensive Cancer Network: JNCCN. 2011; 9:830-887.
4. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012; 118:2632-2640.
5. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, et al. Targeting Mcl-1 for the therapy of cancer. Expert opinion on investigational drugs. 2011; 20:1397-1411.
6. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell death and differentiation. 2011; 18:1414-1424.
7. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:1126-1132.
8. McCabe ML, Dlamini Z. The molecular mechanisms of oesophageal cancer. International immunopharmacology. 2005; 5:1113-1130.
9. Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, et al. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia. 2013; 27:1996-2005.
10. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:909-916.
11. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer research. 2008; 68:3421-3428.
12. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood. 2012; 119:5807-5816.
13. Zhao X, Ogunwobi OO, Liu C. Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PloS one. 2011; 6:e21980.
14. Ackler S, Mitten MJ, Chen J, Clarin J, Foster K, Jin S, Phillips DC, Schlessinger S, Wang B, Leverson JD, et al. Navitoclax (ABT-263) and bendamustine +/-rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. British journal of pharmacology. 2012; 167:881-891.
15. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:3163-3169.
16. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007; 128:1173-1186.
17. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Schlessinger S, Wang B, Chemburkar SR, Bauch J, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular cancer therapeutics. 2008; 7:3265-3274.
18. Sakariassen PO, Immervoll H, Chekenya M. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia. 2007; 9:882-892.
19. Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, et al. Reciprocal regulation by TLR4 and TGFbeta in tumor-initiating stem-like cells. The Journal of clinical investigation. 2013; 123:2832-2849.
20. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer research. 2014; 74:4170-4182.
21. Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, Ardail D, Rodriguez-Lafrasse C, Magne N. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer letters. 2012; 322:139-147.
22. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21:2580-2590.
23. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007; 26:5674-5679.
24. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12:6565-6572.
25. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al. The crosstalk of mTOR/ S6K1 and Hedgehog pathways. Cancer cell. 2012; 21:374-387.
26. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:2130-2139.
27. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:12405-12410.
28. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, et al. Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells. Cancer Res. 2014; 74:4170-4182.
29. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1988; 6:1653-1664.
30. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC cancer. 2010; 10:370.
31. Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA, Milas L. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2006; 80:185-191.
32. Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer biology & therapy. 2008; 7:986-994.
33. Jingu K, Matsushita H, Takeda K, Umezawa R, Takahashi C, Sugawara T, Kubozono M, Abe K, Tanabe T, Shirata Y, et al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC cancer. 2012; 12:542.
34. Jerhammar F, Johansson AC, Ceder R, Welander J, Jansson A, Grafstrom RC, Soderkvist P, Roberg K. YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral oncology. 2014; 50:832-839.
35. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014; 158:171-184.
36. Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z, Chen J. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncology reports. 2013; 29:840-846.
37. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung MC, Bresalier RS. Galectin-3 mediates nuclear betacatenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer research. 2009; 69:1343-1349.
38. Zhao B, Kim J, Ye X, Lai ZC, Guan KL. Both TEADbinding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer research. 2009; 69:1089-1098.
39. Song S, Maru DM, Ajani JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, et al. Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer research. 2013; 73:2159-2169.
40. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular oncology. 2014; 8:142-149.
41. Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003; 16:17-23.
42. Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, Meng S, Wang Y, Yuan Z, Bi W. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 2014; 33:1468-1474.
43. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015; 21:2580-2590.
44. Song S, Krishnan K, Liu K, Bresalier RS. Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:622-631.
45. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clinical proteomics. 2010; 6:129-151.